Janus Henderson Investors is extending the availability of two existing investment funds to Singapore and introduce a newly available fund to both retail and institutional clients in the region, the global asset manager announced on March 11.

Previously available in Hong Kong and Taiwan, both the Janus Henderson Global Life Sciences Fund and the Janus Henderson Balanced Fund are now offered in Singapore to retail clients. The Janus Henderson Emerging Markets Leaders Fund is new to Asian markets and will be available to both retail and institutional investors in Singapore.

The Janus Henderson Balanced Fund invests in a blend of US bonds and equities. The fund differentiates itself through a bottom-up equities and fixed income portfolio weightings approach, with capital allocation between bonds and equities.

The Janus Henderson Global Life Sciences Fund invests in innovative life science companies. This encompasses firms operating in healthcare, biotechnology and pharmaceutical innovators, healthcare service providers and medical device firms.

The Janus Henderson Emerging Markets Leaders Fund is a high conviction strategy that seeks to achieve long-term growth of capital by investing in developing market stocks. The fund is available to both retail and institutional investors. All three funds are domiciled in Ireland.